# ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
> **ANDA212181** · Abbreviated New Drug Application (Generic) · Sponsor: EMCURE PHARMS LTD · Approved 2024-12-05
## Drug
- **FDA Application Number:** ANDA212181
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
- **Generic name:** Abacavir || Dolutegravir || Lamivudine
- **Active ingredients:** ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
- **Dosage form:** TABLET
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** EMCURE PHARMS LTD
- **First approval:** 2024-12-05
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212181)
---
*MORVS · CC0 1.0*